PT  - JOURNAL ARTICLE
AU  - Paredes, Miguel I.
AU  - Ahmed, Nashwa
AU  - Figgins, Marlin
AU  - Colizza, Vittoria
AU  - Lemey, Philippe
AU  - McCrone, John T.
AU  - Müller, Nicola
AU  - Tran-Kiem, Cécile
AU  - Bedford, Trevor
TI  - Early underdetected dissemination across countries followed by extensive local transmission propelled the 2022 mpox epidemic
AID  - 10.1101/2023.07.27.23293266
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.27.23293266
4099  - http://medrxiv.org/content/early/2023/12/07/2023.07.27.23293266.short
4100  - http://medrxiv.org/content/early/2023/12/07/2023.07.27.23293266.full
AB  - The World Health Organization declared mpox a public health emergency of international concern in July 2022. To investigate global mpox transmission and population-level changes associated with controlling spread, we built phylogeographic and phylodynamic models to analyze MPXV genomes from five global regions together with air traffic and epidemiological data. Our models reveal community transmission prior to detection, changes in case-reporting throughout the epidemic, and a large degree of transmission heterogeneity. We find that viral introductions played a limited role in prolonging spread after initial dissemination, suggesting that travel bans would have had only a minor impact. We find that mpox transmission in North America began declining before more than 10% of high-risk individuals in the USA had vaccine-induced immunity. Our findings highlight the importance of broader routine specimen screening surveillance for emerging infectious diseases and of joint integration of genomic and epidemiological information for early outbreak control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMIP and MF are ARCS Foundation scholars. MF was supported by the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE1762114. T.B. is a Howard Hughes Medical Institute Investigator. This work was supported by NIH NIGMS award R35 GM119774 to T.B. Analyses were completed using Fred Hutch Scientific Computing resources (NIH grants S10-OD-020069 and S10-OD-028685).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes